Superbugs & Superdrugs USA

New Jersey, USA (November, 12 - 13, 2018)

To address the ever-growing need of informative and thought-provoking discussions, SMi 3^rd annual Superbugs & Superdrugs USA conference will offer a jam-packed agenda with presentations from key industry leaders and up-and-coming thinkers, within the field.

This years' Superbugs & Superdrugs USA conference programme will help participants to learn about pathogen focused drug development; discover the best methods to overcome bacterial resistance through novel modes of action; discuss the state of developments within the antifungal space; develop an understanding of funding opportunities which support antibacterial research and development; gain insight into new techniques through case-study examples of rapid diagnostic methods currently being used within the field, making this event the perfect platform to strengthen knowledge in key principles.

Speakers include:

·         Anthony Simon Lynch, Senior Scientific Director, Janssen

·         William Weiss, Director, Pre-Clinical Services, UNT Health Science Center

·         Tina Guina, Program Officer, Drug Development Section, NIAID/NIH

·         Mark Albrecht, Project Officer, HHS/ASPR/BARDA

·         Antonio DiGiandomenico, Principal Scientist, MedImmune

·         Andrew Tomaras, VP & Director of Microbiology, Bacterioscan

·         Dan Pevear, Sr Vice President & Director of Microbiology, VenatoRx

·         Ian Friedland, Clinical Consultant, ex-CMO, Achaogen

Plus, topical workshops on November 14:

·         Rapid diagnostics for drug resistance: Are we there yet?

·         Avoiding the post antibiotic era: the challenges and solutions to successful commercialisation of new antibiotics

Further details at http://www.superbugs-usa.com/G2B

Twitter - @SMIpharm & #smibugs

LinkedIn - SMi Pharma

CONTACT:

+44 (0)20 7827 6000